alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                                  <C>                    <C>
<PERIOD-TYPE>                        12-MOS                 3-MOS
<FISCAL-YEAR-END>                    DEC-31-1999            DEC-31-1999
<PERIOD-START>                       JAN-01-1999            JAN-01-2000
<PERIOD-END>                         DEC-31-1999            MAR-31-2000
<CASH>                               68,000                 0
<SECURITIES>                         0                      0
<RECEIVABLES>                        0                      0
<ALLOWANCES>                         0                      0
<INVENTORY>                          0                      0
<CURRENT-ASSETS>                     130,000                88,000
<PP&E>                               287,000                289,000
<DEPRECIATION>                       (42,000)               (66,000)
<TOTAL-ASSETS>                       3,406,000              8,722,000
<CURRENT-LIABILITIES>                972,000                1,218,000
<BONDS>                              0                      0
<PREFERRED-MANDATORY>                0                      0
<PREFERRED>                          0                      0
<COMMON>                             36,000                 42,000
<OTHER-SE>                           2,398,000              7,462,000
<TOTAL-LIABILITY-AND-EQUITY>         3,406,000              8,722,000
<SALES>                              0                      0
<TOTAL-REVENUES>                     0                      0
<CGS>                                0                      0
<TOTAL-COSTS>                        0                      0
<OTHER-EXPENSES>                     (5,652,000)            (6,514,000)
<LOSS-PROVISION>                     0                      0
<INTEREST-EXPENSE>                   (84,000)               (59,000)
<INCOME-PRETAX>                      (5,686,000)            (6,573,000)
<INCOME-TAX>                         0                      0
<INCOME-CONTINUING>                  (5,686,000)            (6,573,000)
<DISCONTINUED>                       0                      0
<EXTRAORDINARY>                      0                      0
<CHANGES>                            0                      0
<NET-INCOME>                         (5,686,000)            (6,573,000)
<EPS-BASIC>                          (1.99)                 (1.78)
<EPS-DILUTED>                        (1.99)                 (1.78)



</TABLE>
Exhibit 13.1








FERRARI N.V.


CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Sergio Marchionne, Chief Executive Officer and Director of of Ferrari N.V. (the “Company”), hereby certify pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:


|   |                                                                                                                                                                                                                                                                         
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|1. | the Company’s Annual Report on Form 20-F for the year ended December 31, 2016, to which this statement is furnished as an exhibit (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

|   |                                                                                                                                                     
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------
|2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.










Date: March 3, 2017by:/s/ Sergio MarchionneSergio MarchionneChief Executive Officer and Director








A signed original of this written statement has been provided to Ferrari N.V. and will be retained by Ferrari N.V. and furnished to the Securities and Exchange Commission or its staff upon request.


The foregoing certification is being furnished solely pursuant to 18 U.S.C §1350 and is not being filed as part of the Report or as a separate disclosure document.
EXHIBIT 99.2
                                  CERTIFICATION

                       Pursuant to 18 U.S.C. Section 1350,
                             As Adopted Pursuant to
                  Section 906 of the Sarbanes-Oxley Act of 2002


     Pursuant to 18 U.S.C.  Section 1350, as adopted  pursuant to Section 906 of
the Sarbanes-  Oxley Act of 2002,  and in  connection  with the annual report on
Form  10-KSB of  Volunteer  Bancorp,  Inc.  (the  "Company")  for the year ended
December 31, 2002, as filed with the Securities  and Exchange  Commission on the
date hereof (the "Report"), the undersigned, Greg Oliver, the Vice President and
Cashier of the Company, hereby certifies that (1) the Report fully complies with
the  requirements  of Section 13(a) or 15(d) of the  Securities  Exchange Act of
1934, and (2) the information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

     This Certification is signed on March 28, 2003.


                                        /s/ Greg Oliver
                                        ----------------------------------------
                                        Greg Oliver
                                        Vice President and Cashier
<PAGE>   1
                                                                    Exhibit 23.2





                       CONSENT OF INDEPENDENT ACCOUNTANTS

   
We consent to the inclusion in Intracel Corporation's registration statement on 
Form S-1 (File No. 333-58819) of our report dated April 2, 1998, except for the 
second paragraph of Note 14 as to which the date is June 8, 1998, on our audit 
of the 1997 financial statements of Perimmune Holdings, Inc. and Subsidiary. We 
also consent to the reference to our firm under the caption "Experts".



/s/ PricewaterhouseCoopers LLP


PricewaterhouseCoopers LLP
McLean, Virginia
December 31, 1998
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 20
- 0136 STATE OF MONTANA,

Plaintiff and Appellee, v. WALTER LEE TERRY,

Defendant and Appellant
.

**ORDER** Upon consideration of Appellant’s motion for extension of time, and good cause appearing, IT IS HEREBY ORDERED that Appellant is granted an extension of time to and including August 17 , 2020 , within which to prepare, file, and serve Appellant’s opening brief on appeal.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

July 10 2020

07/10/2020

Case Number: DA 20-0136
IIB 

118TH CONGRESS 

2D SESSION H. R. 7858 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 18, 2024 

Received; read twice and referred to the 

AN ACT 

To amend title XVIII of the Social Security Act to establish 

a Medicare incident to modifier for mental health services 

furnished through telehealth and other telehealth services. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

HR 7858 RFS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Telehealth Enhance3 ment for Mental Health Act of 2024’’ or the ‘‘TELEMH 

4 Act of 2024’’. 

5 SEC. 2. ESTABLISHMENT OF MEDICARE INCIDENT TO 

6 MODIFIER FOR MENTAL HEALTH SERVICES 

7 FURNISHED THROUGH TELEHEALTH AND 

8 OTHER TELEHEALTH SERVICES. 

9 Section 1834(m) of the Social Security Act (42 

10 U.S.C. 1395m(m)) is amended by adding at the end the 

11 following new paragraph: 

12 ‘‘(10) REQUIRED USE OF MODIFIERS IN CER13 TAIN INSTANCES.—Not later than January 1, 2026, 

14 the Secretary shall establish requirements to include 

15 a code or modifier, as determined appropriate by the 

16 Secretary, in the case of claims for telehealth serv17 ices under this subsection that are billed incident to 

18 a physician’s or practitioner’s professional service.’’. 

Passed the House of Representatives September 17, 

2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


ssavage on LAPJG3WLY3PROD with BILLS
# C_2014093EN.01002701.xml

| 29.3.2014 | EN | Official Journal of the European Union | C 93/27 |
| --- | --- | --- | --- |

29.3.2014

EN

Official Journal of the European Union

C 93/27

---

Action brought on 22 January 2014 — Czech Republic v Commission

(Case T-51/14)

2014/C 93/47

Language of the case: Czech

Parties

Parties

Applicant: Czech Republic (represented by: M. Smolek, J. Vláčil, J. Vikáková, Agents)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the implementing decision of the European Commission C(2013) 7615 of 13 November 2013 on the rejection of an application for entry in the register of traditional specialities guaranteed provided for in Regulation (EU) No 1151/2012 (1) of the European Parliament and of the Council (Pomazánkové máslo (TSG)) and |
| --- | --- |

—

Annul the implementing decision of the European Commission C(2013) 7615 of 13 November 2013 on the rejection of an application for entry in the register of traditional specialities guaranteed provided for in Regulation (EU) No 1151/2012 (1) of the European Parliament and of the Council (Pomazánkové máslo (TSG)) and

1

| — | Order the European Commission to pay the costs. |
| --- | --- |

—

Order the European Commission to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

In support of the action, the applicant relies on one plea in law, alleging the infringement of Articles 50 and 52 of Regulation No 1151/2012 in conjunction with Article 18 thereof. The applicant submits that the Commission did not scrutinise whether the conditions were met for the entry of the name ‘Pomazánkové máslo’ as a traditional speciality guaranteed and rejected the application in question for a reason other than the fact that it did not meet those conditions.

---

(1)  Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (OJ 2012 L 343, p. 1).

1

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1210 Continuous flush catheter. ( a ) *Identification.* A continuous flush catheter is an attachment to a catheter-transducer system that permits continuous intravascular flushing at a slow infusion rate for the purpose of eliminating clotting, back-leakage, and waveform damping.
( b ) *Classification.* Class II (performance standards).
#### § 1.1019-1 Property on which lessee has made improvements.

In any case in which a lessee of real property has erected buildings or made other improvements upon the leased property and the lease is terminated by forfeiture or otherwise resulting in the realization by such lessor of income which, were it not for the provisions of section 109, would be includible in gross income of the lessor, the amount so excluded from gross income shall not be taken into account in determining the basis or the adjusted basis of such property or any portion thereof in the hands of the lessor. If, however, in any taxable year beginning before January 1, 1942, there has been included in the gross income of the lessor an amount representing any part of the value of such property attributable to such buildings or improvements, the basis of each portion of such property shall be properly adjusted for the amount so included in gross income. For example, A leased in 1930 to B for a period of 25 years unimproved real property and in accordance with the terms of the lease B erected a building on the property. It was estimated that upon expiration of the lease the building would have a depreciated value of $50,000, which value the lessor elected to report (beginning in 1931) as income over the term of the lease. This method of reporting was used until 1942. In 1952 B forfeits the lease. The amount of $22,000 reported as income by A during the years 1931 to 1941, inclusive, shall be added to the basis of the property represented by the improvements in the hands of A. If in such case A did not report during the period of the lease any income attributable to the value of the building erected by the lessee and the lease was forfeited in 1940 when the building was worth $75,000, such amount, having been included in gross income under the law applicable to that year, is added to the basis of the property represented by the improvements in the hands of A. As to treatment of such property for the purposes of capital gains and losses, see subchapter P (section 1201 and following), chapter 1 of the Code.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                          49,626
<SECURITIES>                                    27,077
<RECEIVABLES>                                    9,465
<ALLOWANCES>                                       707
<INVENTORY>                                     20,265
<CURRENT-ASSETS>                               111,698
<PP&E>                                          27,970
<DEPRECIATION>                                   9,851
<TOTAL-ASSETS>                                 153,919
<CURRENT-LIABILITIES>                           22,966
<BONDS>                                         11,630
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        310
<OTHER-SE>                                     118,943
<TOTAL-LIABILITY-AND-EQUITY>                   153,919
<SALES>                                         64,411
<TOTAL-REVENUES>                                     0
<CGS>                                           49,083
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                37,908
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,303
<INCOME-PRETAX>                               (19,475)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (19,475)
<EPS-PRIMARY>                                    (.63)
<EPS-DILUTED>                                    (.63)
        

</TABLE>
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3225 Enterovirus nucleic acid assay. ( a ) *Identification.* An enterovirus nucleic acid assay is a device that consists of primers, probes, enzymes, and controls for the amplification and detection of enterovirus ribonucleic acid (RNA) in cerebrospinal fluid (CSF) from individuals who have signs and symptoms consistent with meningitis or meningoencephalitis. The detection of enterovirus RNA, in conjunction with other laboratory tests, aids in the clinical laboratory diagnosis of viral meningitis caused by enterovirus.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Nucleic Acid Amplification Assay for the Detection of Enterovirus RNA.” See § 866.1(e) for the availability of this guidance document.
[74 FR 8, Jan. 2, 2009]
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1850 Radiographic film cassette. ( a ) *Identification.* A radiographic film cassette is a device intended for use during diagnostic x-ray procedures to hold a radiographic film in close contact with an x-ray intensifying screen and to provide a light-proof enclosure for direct exposure of radiographic film.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
[48 FR 53047, Nov. 23, 1983, as amended at 84 FR 71819, Dec. 30, 2019]
Exhibit 99.2

                          CERTIFICATION PURSUANT TO
                           18 U.S.C. SECTION 1350,
                            AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


 In connection with the Quarterly Report of American HealthChoice, Inc.  (the
 "Company") on Form 10-QSB for the period ending June 30, 2002 as filed  with
 the Securities and Exchange Commission on the date hereof (the "Report"),  I
 John C. Stuecheli, Chief Financial Officer of the Company, certify, pursuant
 to 18 U.S.C. S 1350, as adopted pursuant to S 906 of the Sarbanes-Oxley  Act
 of 2002, that to the best of my knowledge and belief:

      (1)  The Report fully complies with  the requirements of Section  13(a)
 or 15(d) of the Securities Exchange Act of 1934; and

      (2)  The information contained  in the Report  fairly presents, in  all
 material respects, the financial condition and  result of operations of  the
 Company.


 /s/ John C. Stuecheli
 -----------------------
 John C. Stuecheli
 Chief Financial Officer

 August 14, 2002
# Fourth Court of Appeals

**San Antonio, Texas**

JUDG MENT

No. 04

- 24

- 00403

- CV

Lydia MARTINEZ

, Appellant

v.

33 REAL CONSTRUCTION LLC

, Appellee

From the County Court at Law No

. 2

, Webb County, Texas

Trial Court No. 2024CVD000002L2

Honorable Victor Villarreal , Judge Presiding

BEFORE JUSTICE CHAPA

, JUSTICE RIOS , AND JUSTICE WATKINS

In accordance with this court’s opinion of this date, this appeal is DISMISSED FOR

WANT OF PROSECUTION. We order all costs of this appeal to be taxed against appellant

.

SIGNED August 21, 2024.

_________________________________ Luz Elena D. Chapa , Justice
## F IRST 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________
No. 1D 18

- 3104

_____________________________
L EE S HIVER , Appellant,

v.

S TATE OF F LORIDA , Appellee.

_____________________________

On appeal from the Circuit Court for Suwan nee County

. David W. Fina , Judge

. February 12, 2019

P ER C URIAM

.
A FFIRMED

. B.L. T HOMAS , C.J., and B ILBREY and J AY , JJ., concur.

_____________________________ Not final until disposition of any timely and authorized motion under Fla. R. App. P. 9.330 o r 9.331

.

_____________________________2 Lee Shiver, pro se
, Appellant.

Ashley B

. Moody , Attorney General, and Holly N. Simcox, Assistant Attorney General, Tallahassee
, for Appellee.
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.4950 Diagnostic neurosurgical microscope filter. ( a ) *Identification.* A diagnostic neurosurgical microscope filter is a device intended for use during neurosurgery to visualize fluorescence and enhance visualization of tissue associated with a specific disease or condition.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, and verify and validate filter specifications and functional characteristics, including the following: ( i ) Spectrum and intensity of the illumination source;
( ii ) Spectrum of the excitation and emission filter modules when integrated in the surgical operating microscope;
( iii ) Excitation power and power density;
( iv ) Optical path loss from illumination source to objective lens or microscope camera;
( v ) Homogeneity of the excitation light at the focal plane;
( vi ) Fluorescence detection sensitivity;
( vii ) Verification of calibration or preoperative procedures; and
( viii ) If camera-based, spectral sensitivity of the camera.
( 2 ) Labeling must include: ( i ) Identification of the filter characteristics in conjunction with a compatible surgical operating microscope, to include the following: ( A ) Illumination spectrum and power density; and
( B ) Excitation and emission filter spectra.
( ii ) Instructions for calibration or preoperative checks to ensure device functionality prior to each use;
( iii ) Instructions for use with compatible surgical operating microscopes, external light sources, and cameras;
( iv ) A warning that the device should only be used with fluorophores approved for use within the specified spectral ranges; and
( v ) A warning that the device is not a standalone diagnostic.
[86 FR 73973, Dec. 29, 2021]
<PAGE>  1




-----------------------------------------------------------------------------
           UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                       Washington, D.C. 20549
                                10-Q
(Mark One)
        /x/  Quarterly Report Pursuant to Section 13 or Section 15(d)
             of the Securities Exchange Act of 1934

             For the quarterly period ended September 28, 1996
             
OR

        / /  Transition report pursuant to Section 13 or 15(d) of the
             Securities Exchange Act of 1934

             For the transition period from __________ to __________.
  
Commission File No. 0-18033

                         EXABYTE CORPORATION
         (Exact name of registrant as specified in its charter)


       Delaware                        84-0988566
(State of Incorporation)     (I.R.S. Employer Identification No.)

                          1685 38th Street
                      Boulder, Colorado  80301
     (Address of principal executive offices, including zip code)



                          (303) 442-4333
         (Registrant's Telephone Number, including area code)


     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past ninety days.

      Yes          /X/                      No          /  /


As of November 6, 1996, there were 22,126,787 shares outstanding of the
Registrant's Common Stock (par value $0.001 per share).

-----------------------------------------------------------------------------






<PAGE> 2

PART II.




Item 6.  Exhibits and Reports on Form 8-K

(a)     Exhibit Index

          Exhibit
          Number               Description
          -------              -----------
          27.0                 Financial Data Schedule



(b)     Reports on Form 8-K:  There were no reports on Form 8-K for the
          three month period ended September 28, 1996








































<PAGE> 3





SIGNATURES
----------


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                  EXABYTE CORPORATION
                                  Registrant



Date                                 By   /s/Stephen F. Smith
      -----------------------             ------------------------
                                         Vice President, Chief Financial
                                         Officer, General Counsel and Secretary
                                         (Principal Financial and Accounting
                                         Officer)